An open-label randomized trial to determine the most effective regimen of vaginal estrogen to reduce the prevalence of atrophic changes reported in postmenopausal cervical smears

Menopause

Volumn 16, Issue 4, 2009, Pages 765-769

  Bateson, Deborah J ^a   Weisberg, Edith ^a  

^a FAMILY PLANNING NSW   (Australia)

Author keywords

Atrophic smear; Pap smear; Postmenopause; Vaginal estrogen

Indexed keywords

ESTROGEN;

ADULT; AGED; ARTICLE; AUSTRALIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; EVENING DOSAGE; FALSE POSITIVE RESULT; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; OPEN STUDY; OPTIMAL DRUG DOSE; PAPANICOLAOU TEST; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; UTERINE CERVIX CYTOLOGY; VAGINA ATROPHY;

ADMINISTRATION, INTRAVAGINAL; ADULT; AGED; ATROPHY; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTRADIOL; FEMALE; HUMANS; MIDDLE AGED; ODDS RATIO; POSTMENOPAUSE; VAGINA; VAGINAL SMEARS;

EID: 68449093178     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e318193e7cd     Document Type: Article

References (17)

1. Garland S. Can we really beat cervical cancer? Med J Aust 2003;178:647-650.
2. Cervical cancer still falling, but higher screening rates sought. Australian Institute of Health and Welfare. 2004. Available at: http://www.aihw.gov.au/mediacentre/2004/mr20041118a.cfm. Accessed August 12, 2008.
3. Sturrock C, Goodwin M. Australia's national cancer screening programs. Australian Institute of Health and Welfare. 2008. Available at: http://www.aihw.gov.au/eventsdiary/ah08/presentations/australia-s-national- cancer-screening-programs-sturrock-c-goodwin-m.pdf. Accessed August 12, 2008.
4. Waddell CA. The influence of the cervix on smear quality. I: atrophy. An audit of cervical smears taken post-colposcopic management of intraepithelial neoplasia. Cytopathology 1997;8:274-281.
5. Gupta S, Kumar N, Singhal N, Manektala U, Jain S, Sodhani P. Cytohormonal and morphological alterations in cervicovaginal smears of postmenopausal women on hormone replacement therapy. Diagn Cytopathol 2006;34:676-680.
6. Abati A, Jaffurs W, Wilder AM. Squamous atypia in the atrophic cervical vaginal smear. Cancer Cytopathol 1998;84:218-225.
7. Kaminski PF, Sorosky JI, Wheelock JB, Stevens CW. The significance of atypical cervical cytology in an older population. Obstet Gynecol 1989;73:13-15.
8. Clocuh YPA. The administration of oestrogen since the interpretation of doubtful atrophic cytosmears. Geburtshilfe Frauenheilk 1980;40:1121-1129.
9. Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev 2006, Issue 2. Art No: CD001500.
10. Manonai J, Chittacharoen A, Theppisai U. Transvaginal color Doppler sonographic assessment of uterus and ovaries in postmenopausal women: the effect of local estrogen treatment. Eur J Obstet Gynecol Reprod Biol 2006;127:222-226.
11. Yasuya K, Sadaharu I, Yasuki S, Mori T. Colposcopy for post menopausal women. Gynecol Oncol 1985;20:62-70.
12. SAS Proprietary Software Release 9.0, 2002. Cary, NC: SAS Institute Inc.
13. Repse-Fokter A, Fokter SK, Komadina R, Stiblar-Martinic D, Takac I. Morphological analysis of squamous cells in routine Pap smears as a predictor of bone mineral density in asymptomatic women. Eur J Obstet Gynecol Reprod Biol 2004;113:221-225.
14. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288:321-333.
15. Canfell K, Banks E, Moa AM, Beral V. Decrease in breast cancer incidence following a rapid fall in use of hormone replacement therapy in Australia. Med J Aust 2008;188:641-644.
16. Clarke CA, Glaser SL, Uratsu CS, Selby JV, Kushi LH, Herrinton LJ. Recent declines in hormone therapy utilization. J Clin Oncol 2006;24:49-50.
17. Mitchell HS. Longitudinal analysis of histologic high-grade disease after negative cervical cytology according to cytological status. Cancer 2001;93:237-240.